Elif Sertesen

university of health science

H指数:3

被引数:36

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers: National, Comparative, Observational Study (TOG/GI-SAFRADJU-2501)

切除后胆道癌的辅助化疗方案：国家性、比较性、观察性研究（TOG/GI-SAFRADJU-2501）

International Journal of Cancer

IF4.7

2026-08-150

OAAI

Erman Akkus; Mehmet Kayaalp; Müzeyyen Aslı Ergözoğlu; Ilgın Koç Kuş; Doğan Bayram; Bilgeşah Kılıçtaş; Emel Ayvaz Güneyin; Ali Kalem; Haydar Temizyürek; Mehmet Mutlu Çatlı; Mehmet Sinan Akarca; Maral Martin Mıldanoğlu; Görkem Turhan; Mahmut Kara; Hacı Arak; Feyza Arslan Tan; Burak Paçacı; Berkay Yeşilyurt; Orhun Akdoğan; Emine Bihter Çetin; Selahattin Çelik; Fatma Keskin Uzundere; Elif Şahin; Zehra Sadak Öcal; Lamia Şeker Can; Bahadır Köylü; Mehmet Cem Fidan; Esmanur Kaplan Tüzün; Teoman Şakalar; Elif Sertesen Çamöz; Haydar Çağatay Yüksel; Onur Yazdan Balçık; Pınar Peker; Mehmet Yılmaz; Şeymanur Ala Enli; Erdem Kölemen; Sibel Oyucu Orhan; Yakup Düzköprü; Mustafa Ersoy; Tuğba Akın Telli; Mesut Yılmaz; Yusuf İlhan; Atila Yıldırım; Ramazan Coşar; Müslih Ürün; Arif Hakan Önder; Murat Araz; Ertuğrul Bayram; Havva Yeşil Çınkır; Ali Alkan; Mustafa Gürbüz; Nilüfer Avcı; Fatma Paksoy Türköz; İsmail Oğuz Kara; Fatih Köse; İlkay Tuğba Ünek; Ahmet Bilici; Öznur Bal; Şuayib Yalçın; Lorenza Rimassa; Hatime Arzu Yaşar

Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

Gustave Roussy免疫评分对接受一线免疫疗法为基础的联合治疗转移性肾细胞癌的预后影响：土耳其肿瘤学组肾癌联盟（TKCC）的研究结果

BMC Cancer

IF3.4

2026-08-060

Beyond Histology: A Dual-Cohort Genomic Analysis of 2901 Endometrial Carcinomas Reveals Class-Level Mismatch Repair Effects and Refines Molecular Classification

超越组织学：一项包含2901例子宫内膜癌的双队列基因组分析揭示了类别水平的错配修复效应并细化了分子分类

Genes

IF2.8

2026-05-220

Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

卡博替尼与舒尼替尼在晚期非透明细胞肾细胞癌中的真实世界比较：土耳其肿瘤学集团的多中心研究

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2025-09-010

PRE

Sahin, Gokhan; Tuzun, Esmanur Kaplan; Guzel, Halil G.; Guliyev, Murad; Disli, Ahmet K.; Yazici, Melike; Yildiz, Oguzhan; Gunes, Tugce K.; Alkan, Suleyman; Kahraman, Emir G.; Ozel, Gamze Serin; Icli, Mehmet C.; Sahin, Elif; Muglu, Harun; Acar, Caner; Tunbekici, Salih; Yuksel, Haydar C.; Yucel, Hakan; Kahya, Burcu Ulas; Kitapli, Sait; Buyuksimsek, Mahmut; Ipek, Suheda A.; Dama, Pinar E.; Usta, Ekin Akyildiz; Yilmaz, Mesut; Asik, Esra; Ozalp, Faruk R.; Savsar, Mehmet G.; Kocaaslan, Erkam; Sim, Saadet; Agaoglu, Ahmet B.; Camoz, Elif Sertesen; Demir, Teyfik; Uyar, Galip C.; Yildirim, Atila; Cinkir, Havva Y.; Salim, Derya Kivrak; Dogu, Gamze Gokoz; Alan, Ozkan; Bayram, Ertugrul; Karacin, Cengiz; Guc, Zeynep G.; Ekinci, Ferhat; Eryilmaz, Melek Karakurt; Semiz, Huseyin S.; Unal, Olcun U.; Goksu, Sema Sezgin; Ozturk, Banu; Inanc, Mevlude; Uygun, Kazim; Hacibekiroglu, Ilhan; Ercolak, Vehbi; Kara, Ismail O.; Yazici, Ozan; Bilici, Ahmet; Tanriverdi, Ozgur; Karaca, Burcak; Erman, Mustafa; Gokmen, Erhan; Goker, Erdem; Yildirim, Hasan Cagri

The impact of smoking on nivolumab outcomes in renal cell carcinoma: real-world data from the Turkish Oncology Group Kidney Cancer Consortium

吸烟对纳武利尤单抗治疗肾细胞癌结局的影响：土耳其肿瘤学组肾癌联盟的真实世界数据

ONCOLOGIST

IF4.2

2025-07-010

PRE

Letter re: Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting

函件：关于CDK4/6抑制剂联合芳香化酶抑制剂在美国真实世界环境中HR+/HER2−转移性乳腺癌中总生存比较

ESMO Open

IF8.3

2025-06-010